CTNI-39. REGOMA-OS: A LARGE ITALIAN MULTICENTER, PROSPECTIVE, OBSERVATIONAL STUDY ANALYZING REGORAFENIB EFFICACY AND SAFETY IN RECURRENT GLIOBLASTOMA PATIENTS

Abstract BACKGROUND in the randomized phase 2 REGOMA trial, regorafenib (REG) showed promising activity in recurrent glioblastoma (GBM) patients (PTS); subsequently, in Italy the National Health System has permitted the reimbursement of the REG as second-line therapy. We performed a large multicente...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Neuro-oncology (Charlottesville, Va.) Va.), 2023-11, Vol.25 (Supplement_5), p.v83-v83
Hauptverfasser:	Caccese, Mario, Desideri, Isacco, Villani, Veronica, Simonelli, Matteo, Buglione, Michela, Chiesa, Silvia, Franceschi, Enrico, Gaviani, Paola, Stasi, Irene, Caserta, Claudia, Brugnara, Sonia, Lolli, Ivan, Bennicelli, Elisa, Bini, Paola, Cuccu, Angelo Salvatore, Scoccianti, Silvia, Magni, Giovanna, De Salvo, Gian Luca, Zagonel, Vittorina, Lombardi, Giuseppe
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical Trials: Non-Immunologic
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!